Tribuloside
Based on 2 publication(s) in Google Scholar
Tribuloside is a flavonoid and PDE4 inhibitor (IC50: 6 μM). Tribuloside exhibits antibacterial and antioxidant activities, capable of scavenging DPPH free radicals. Tribuloside also promotes melanogenesis. Tribuloside can be used in the research of hypopigmentary diseases, sun protection, and inflammatory diseases such as acute lung injury.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 98.95%
- CAS. Nr.: 22153-44-2
- Formel: C30H26O13
- Molecular Weight:594.52
-
Speicherung:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Immunology/Inflammation Compound Library
HY-L007
-
Membrane Transporter/Ion Channel Compound Library
HY-L011
-
Metabolism/Protease Compound Library
HY-L012
-
Neuronal Signaling Compound Library
HY-L013
-
Stem Cell Signaling Compound Library
HY-L017
-
TGF-beta/Smad Compound Library
HY-L018
-
Natural Product Library
HY-L021
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Differentiation Inducing Compound Library
HY-L038
-
Reprogramming Compound Library
HY-L039
-
Glycoside Compound Library
HY-L042
-
Antibacterial Compound Library
HY-L049
-
Phenols Library
HY-L057
-
Traditional Chinese Medicine Active Compound Library
HY-L065
-
Flavonoids Library
HY-L068
-
Anti-Alzheimer's Disease Compound Library
HY-L069
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Angiogenesis-Related Compound Library
HY-L088
-
Mechanoreceptors Compound Library
HY-L095
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Antidepressant Compound Library
HY-L108
-
Anti-inflammatory Traditional Chinese Medicine Active Compound Library
HY-L114
-
Plant-Sourced Natural Product Library
HY-L115
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Metabolic Enzyme Compound Library
HY-L146
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Cytokine Inhibitors Library
HY-L161
-
Ion Channel Compound Library
HY-L166
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Tibetan Medicine Compound Library
HY-L191
-
Protein Kinase Compound Library
HY-L196
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library
HY-L209
-
Anti-Rheumatic Arthritis Compound Library
HY-L210
-
Diarrhea-Related Traditional Chinese Medicine Active Compound Library
HY-L224
-
Mongolian Medicine Compound Library
HY-L238
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Tribuloside
More
Biologische Aktivität
|
PDE4 6 μM (IC50) |
IL-1β |
IL-6 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Ehrlich | IC50 |
69.5 μM
Compound: 11
|
Cytotoxicity against mouse Ehrlich carcinoma cells
Cytotoxicity against mouse Ehrlich carcinoma cells
|
[PMID: 19254846] |
| HepG2 | EC50 |
0.155 μM
Compound: Tiliroside
|
Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 hrs
Increase in glucose consumption in insulin-resistant human HepG2 cells after 24 hrs
|
[PMID: 21856048] |
| Monocyte | IC50 |
5.2 μM
Compound: tiliroside
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
| Monocyte | IC50 |
5.2 x 10-6 M
Compound: tiliroside
|
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
Inhibition of procoagulant activity in monocyte from human blood assessed as counteraction of IL1-induced tissue factor expression after 18 hrs
|
[PMID: 8882428] |
Tribuloside exhibits antimycobacterial activity against non-pathogenic Mycobacterium madagascariense and Mycobacterium indicus pranii with MIC values of 0.8-1.6 mg/mL[1].
Tribuloside (0-20 μM; 48 h) significantly increases melanogenesis, promotes dendrite formation, and enhances melanosome maturation and transport in human epidermal melanocytes, which is associated with the PDE/cAMP/PKA pathway[2].
Tribuloside (0-20 μM; 0-48 h) upregulates the expression of proteins related to melanogenesis and melanosome transport in human epidermal melanocytes[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Human epidermal melanocytes (HEMCs)
-
Concentration:0, 5, 10 and 20 μM
-
Incubation Time:0, 4, 12, 24 and 48 h
-
Result:Increased the levels of PMEL-17, tyrosinase, TRP-1, TRP-2 and MITF in a time- and dose-dependent manner.
Raised the levels of Rab27a, Rab17 and Cdc42 in a time- and dose-dependent manner.
Tribuloside (10 mg/kg; intraperitoneal injection; single dose) improves LPS (HY-D1056)-induced acute lung injury in mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male mice aged 6 weeks old (30-40 g) treated LPS (HY-D1056)[3]
-
Dosage:10 mg/kg
-
Administration:Intraperitoneal injection; single dose
-
Result:Significantly alleviated lung tissue inflammation and fibrosis, repaired damaged alveolar structure, increased the number of alveoli and the percentage of alveolar area.
Reduced the expression levels of inflammatory cytokines IL-1β, TNF-α, and IL-6 in bronchoalveolar lavage fluid.
Chemical Information
-
CAS. Nr. 22153-44-2
-
Appearance Solid
-
Molecular Weight 594.52
-
Formel C30H26O13
-
Color Light yellow to yellow
-
SMILES
O=C1C(O[C@@H]2O[C@@H]([C@@H](O)[C@H](O)[C@H]2O)COC(/C=C/C3=CC=C(O)C=C3)=O)=C(C4=CC=C(O)C=C4)OC5=CC(O)=CC(O)=C51
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Ethnopharmacol
Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport. [Abstract]2024 Apr 6:323:117673. PMID: 38158096 -
Lösungsmittel & Löslichkeit
DMSO : 125 mg/mL (210.25 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.21 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Christopher R, et al. A new cinnamoylglycoflavonoid, antimycobacterial and antioxidant constituents from Heritiera littoralis leaf extracts. Nat Prod Res. 2014;28(6):351-8. [Content Brief]
[2]. Cao Y, et al. Tribuloside acts on the PDE/cAMP/PKA pathway to enhance melanogenesis, melanocyte dendricity and melanosome transport. J Ethnopharmacol. 2024 Apr 6;323:117673. [Content Brief]
[3]. Yang Z, et al. Tribuloside: Mechanisms and Efficacy in Treating Acute Lung Injury Revealed by Network Pharmacology and Experimental Validation. Dose Response. 2024 May 8;22(2):15593258241251594. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6820 mL | 8.4101 mL | 16.8203 mL | 42.0507 mL |
| 5 mM | 0.3364 mL | 1.6820 mL | 3.3641 mL | 8.4101 mL | |
| 10 mM | 0.1682 mL | 0.8410 mL | 1.6820 mL | 4.2051 mL | |
| 15 mM | 0.1121 mL | 0.5607 mL | 1.1214 mL | 2.8034 mL | |
| 20 mM | 0.0841 mL | 0.4205 mL | 0.8410 mL | 2.1025 mL | |
| 25 mM | 0.0673 mL | 0.3364 mL | 0.6728 mL | 1.6820 mL | |
| 30 mM | 0.0561 mL | 0.2803 mL | 0.5607 mL | 1.4017 mL | |
| 40 mM | 0.0421 mL | 0.2103 mL | 0.4205 mL | 1.0513 mL | |
| 50 mM | 0.0336 mL | 0.1682 mL | 0.3364 mL | 0.8410 mL | |
| 60 mM | 0.0280 mL | 0.1402 mL | 0.2803 mL | 0.7008 mL | |
| 80 mM | 0.0210 mL | 0.1051 mL | 0.2103 mL | 0.5256 mL | |
| 100 mM | 0.0168 mL | 0.0841 mL | 0.1682 mL | 0.4205 mL |
Tribuloside Related Classifications
HY-N2443 Related Classifications
Powered by Bioz
- Tribuloside
- 22153-44-2
- Phosphodiesterase (PDE)
- Bacterial
- PKA
- Tyrosinase
- TRP Channel
- Microphthalmia Associated Transcription Factor (MITF)
- Interleukin Related
- depigmentation model
- acute lung injury model
- Mycobacterium madagascariense
- Mycobacterium indicus pranii
- human epidermal melanocytes
- Inhibitor
- inhibitor
- inhibit